Etcamah
What Etcamah is used for
Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Etcamah
- Active substance
- camizestrant
- Disease area
- Breast Neoplasms
- Medicine group
- Endocrine therapy
- ATC code
- L02BA05
- Marketing authorisation holder
- AstraZeneca AB
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Etcamah used for?
Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).
What is the active substance in Etcamah?
Etcamah contains camizestrant.
Who makes Etcamah?
The EU marketing authorisation holder is AstraZeneca AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU